LFG
OCUL icon

Larson Financial Group’s Ocular Therapeutix OCUL Stock Holding History

Larson Financial Group’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$511 Hold
52
– – ﹤0.01% 3478
2026
Q1 		$440 Sell
52
-14
-21% -$133 ﹤0.01% 3335
2025
Q4 		$801 Buy
66
+57
+633% +$692 ﹤0.01% 3016
2025
Q3 		$105 Buy
9
+1
+13% +$12 ﹤0.01% 3326
2025
Q2 		$74 Buy
+8
New +$63 ﹤0.01% 3197

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Larson Financial Group's OCUL Position: Q2 2026 in Review

Larson Financial Group held its Ocular Therapeutix (OCUL) position steady in Q2 2026 at 52 shares worth $511. The position accounts for ﹤0.01% of the portfolio, ranked #3478.

Larson Financial Group first reported a position in OCUL in Q2 2025 and has held it in 5 quarters since. The position peaked at $801 in Q4 2025. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Larson Financial Group held 52 shares of Ocular Therapeutix worth $511 as of Q2 2026.
  • Larson Financial Group left its Ocular Therapeutix share count unchanged in Q2 2026.
  • Ocular Therapeutix made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #3478 holding.
  • Larson Financial Group first reported a position in Ocular Therapeutix in Q2 2025 and has held it in 5 quarters since.
  • Larson Financial Group's Ocular Therapeutix position peaked at $801 in Q4 2025.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.